文献速递神经肿瘤

术中放疗治疗复发性高级别胶质瘤的疗效与安全性:一项单中心前瞻性研究

The Efficacy and Safety of Intraoperative Radiotherapy in the Treatment of Recurrent High-Grade Glioma: A Single-Center Prospective Study.
PubMed 文献 · World Neurosurg · 2023-01-19

这项单中心前瞻性随机研究自2018年4月开始,将年龄≥18岁、卡氏功能状态评分>50的复发性高级别胶质瘤患者按1:1随机分配至肿瘤切除联合术中放疗(IORT)组或单纯肿瘤切除组。IORT组无进展生存期9.6个月,手术组7.3个月(P=0.018);总生存期分别为13.5个月和10.2个月(P=0.054)。作者结论认为低能射线30-40 Gy的IORT总体安全有效,但6个月内接受过常规分割放疗的患者不应进行IORT。

要点

  • 复发性高级别胶质瘤患者随机接受肿瘤切除联合IORT或单纯切除,无进展生存期IORT组9.6个月优于手术组7.3个月(P=0.018)。
  • 总生存期IORT组13.5个月 vs 手术组10.2个月(P=0.054),未达统计学显著。
  • 术前卡氏功能状态评分>70和IORT为保护因素;6个月内接受过常规分割放疗者行IORT后第9天死于严重脑水肿。

核心结论

  • 低能射线30-40 Gy的IORT对复发性胶质瘤患者总体安全有效。
  • 作者认为,6个月内接受过常规分割放疗的患者不应进行IORT。

研究设计与样本

  • 单中心前瞻性随机研究,2018年4月开始。
  • 纳入年龄≥18岁、卡氏功能状态评分>50的复发性高级别胶质瘤患者,按1:1随机分配至肿瘤切除联合IORT组或单纯肿瘤切除组。
  • IORT组22例,单纯手术组21例;共42例入组患者的临床数据纳入分析。

主要发现

  • IORT组无进展生存期9.6个月 vs 手术组7.3个月(P=0.018)。
  • IORT组总生存期13.5个月 vs 手术组10.2个月(P=0.054)。
  • 单因素和多因素分析表明,术前卡氏功能状态评分>70和IORT是复发性高级别胶质瘤患者的保护因素。
  • 一名接受IORT前6个月内进行过常规分割放疗的患者,在肿瘤切除联合IORT后第9天死于严重脑水肿。
  • IORT组总手术时间更长,但两组术中出血或不良事件无差异。

临床怎么用

  • 作者认为低能射线30-40 Gy的IORT对复发性胶质瘤患者总体安全有效。
  • 作者认为,6个月内接受过常规分割放疗的患者不应进行IORT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade gliomas are treated following a standard protocol; however, tumor recurrence is almost inevitable. Recurrent high-grade gliomas have an extremely poor prognosis, and there are no clear treatment guidelines. In this stud, we evaluated the safety and effectiveness of intraoperative radiotherapy (IORT) for recurrent high-grade glioma. METHODS: In this prospective randomized study begun in April 2018, patients ≥18 years of age with a Karnofsky Performance Status >50 and recurrent high-grade glioma were randomly assigned in a 1:1 ratio to tumor resection and IORT or tumor resection alone. RESULTS: Twenty-two patients were allocated to the IORT group and 21 to receive surgery only (operation group). Clinical data of 42 enrolled patients were involved in the analysis. The progression-free survival of the IORT group was 9.6 months and of the operation group was 7.3 months (P = 0.018), and the overall survival of the 2 groups was 13.5 months and 10.2 months, respectively (P = 0.054). Univariate and multivariate analysis indicated that preoperative Karnofsky Performance Status >70 and IORT were protective factors for patients with recurrent high-grade glioma. A patient who underwent conventional fractionated radiotherapy within 6 months of receiving IORT died on the ninth day after undergoing tumor resection and IORT because of severe cerebral edema. The total operation time was longer in the IORT group, but there were no differences in intraoperative bleeding or adverse events between the 2 groups. CONCLUSIONS: IORT with low-energy radiography at a dose of 30-40 Gy is generally safe and effective for patients with recurrent glioma. However, IORT should not be performed for patients who have received conventional fractionated radiotherapy within 6 months.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Li L, Qin K, Pan Y, et al. The Efficacy and Safety of Intraoperative Radiotherapy in the Treatment of Recurrent High-Grade Glioma: A Single-Center Prospective Study. World Neurosurg. 2023. PMID: 36682529. doi:10.1016/j.wneu.2023.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。